Welcome to our dedicated page for Evaxion Biotech A/S news (Ticker: $EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion Biotech A/S stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evaxion Biotech A/S's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evaxion Biotech A/S's position in the market.
Evaxion Biotech presented promising data from their Phase 2 trial of the AI-designed cancer vaccine, EVX-01, at the ASCO Annual Meeting 2024. The vaccine, targeting neoantigens in metastatic melanoma patients, showed a specific immune response in all participants. Key findings include a 71% neoantigen-triggered T-cell response, involvement of both CD4+ and CD8+ T-cells, and no significant safety concerns. The data further validate Evaxion’s AI-Immunology™ platform's precision. CEO Christian Kanstrup highlighted the potential life-saving impact of EVX-01 and anticipates further data by Q3 2024.
Evaxion Biotech (NASDAQ: EVAX) released its first-quarter 2024 financial results and business update. Key highlights include a net income of $1.2 million, a significant improvement from a $6.2 million loss in Q1 2023, primarily due to the remeasurement of derivative liabilities. The company's cash position improved to $11.7 million from $5.6 million at year-end 2023. Operational highlights include advancements in their AI-Immunology™ platform and upcoming milestones for their vaccine candidates. However, Evaxion received a Nasdaq equity deficiency letter due to IFRS accounting treatment of investor warrants. The company addressed this by converting warrant exercise prices from USD to DKK, eliminating the derivative liability. Despite the positive financial turnaround, Evaxion needs additional funding to sustain operations beyond Q1 2025.
Evaxion Biotech announces positive data from its ongoing Phase 2 study of the personalized cancer vaccine EVX-01 at the American Society of Clinical Oncology (ASCO) Annual Meeting. The study, which combines EVX-01 with anti-PD1 therapy for advanced melanoma patients, reveals that EVX-01 induces strong and specific immune responses mediated by both CD4+ and CD8+ T-cells. Booster shots further enhance these responses without safety concerns. The vaccine demonstrated a good tolerance profile with only minor adverse events. These findings support the potential clinical benefits of EVX-01 and the precision of Evaxion’s AI-Immunology™ platform in selecting effective vaccine targets.
Evaxion Biotech A/S (NASDAQ: EVAX) announced receiving a Nasdaq notification about non-compliance with the minimum stockholders’ equity requirement. The company reported stockholders’ equity below the required amount due to accounting treatment of investor warrants. Nasdaq granted a 45-day period for the company to submit a compliance plan.